Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03687034
Recruitment Status : Not yet recruiting
First Posted : September 27, 2018
Last Update Posted : February 26, 2019
Sponsor:
Information provided by (Responsible Party):
Leaf Vertical Inc.

Tracking Information
First Submitted Date  ICMJE August 22, 2018
First Posted Date  ICMJE September 27, 2018
Last Update Posted Date February 26, 2019
Estimated Study Start Date  ICMJE June 1, 2019
Estimated Primary Completion Date September 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 25, 2018)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Through study completion, an average of one year ]
The primary objective of this study is to evaluate the safety and tolerability of BRCX014 using clinical assessments and lab results.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03687034 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: September 25, 2018)
  • Maximum tolerated dose [ Time Frame: Through study completion, an average of one year ]
    A secondary objective of this study is to identify the maximum tolerated dose of BRCX014.
  • Levels of metabolites [ Time Frame: Through study completion, an average of one year ]
    A secondary objective of this study is to perform pharmacokinetics analyses by measuring the plasma concentrations of BRCX014, temozolomide, and their major metabolites using lab results.
  • Progression-free survival [ Time Frame: Through study completion, an average of one year ]
    A secondary objective of this study is to measure PFS using lab results and radiographic data.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
Official Title  ICMJE A Phase I Study of BRCX014 to Investigate Dose-Ranging Safety and Pharmacokinetics in Adults With Glioblastoma (GBM) and Non-Methylated MGMT Gene Status
Brief Summary An Open-Label, Multi-Center Study to Assess the Safety and Pharmacokinetics of BRCX014 Combined with Standard-of-Care Treatment in Subjects with Glioblastoma
Detailed Description Several studies have shown a possible anti-tumor role for cannabinoids by modulating cell signaling pathways, inhibiting angiogenesis, inducing apoptosis, and overcoming chemotherapy resistance. The investigators seek to demonstrate the safety profile of BRCX014, a cannabinoid formulation, when given to glioblastoma patients in conjunction with standard-of-care therapy.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Intervention Model Description:
This study consists of dose escalations that follow the standard 3+3 design, proceeding until the maximum tolerated dose is attained. The treatment period for patients in this study at each dose will be one year.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glioblastoma
Intervention  ICMJE
  • Drug: Temozolomide
    Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
    Other Name: Temodar
  • Device: Optune
    Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
    Other Name: TTFields
Study Arms  ICMJE Experimental: BRCX014
Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
Interventions:
  • Drug: Temozolomide
  • Device: Optune
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: September 25, 2018)
21
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2020
Estimated Primary Completion Date September 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histopathologically confirmed glioblastoma (astrocytoma WHO grade IV)
  • MGMT promoter methylation status is negative
  • Brain MRI confirmation of disease according to RANO (Response Assessment in Neuro-Oncology) criteria
  • Completion of standard-of-care temozolomide-based chemoradiation for post-operative treatment of glioblastoma plus two-to-six week "washout" period and stable-to-improved baseline brain MRI.
  • Male and female subjects between the ages of 18 and 85 years
  • Karnofsky Performance Score ≥ 60%
  • Expected survival of at least six months from the day of enrollment
  • No severe dysfunction of major organs (e.g., bone marrow, liver, kidneys, heart, lungs, etc.) and laboratory results from up to 14 days prior to enrollment fall within criteria:

    • Hemoglobin > 10 g/dL
    • Leukocytes ≥ 3,000 per μl
    • Absolute neutrophil count ≥ 1,500 per μl
    • Platelet count > 100,000 per μl
    • BUN < 25 mg
    • Serum creatinine within normal institutional limits OR Creatinine clearance ≥ 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal
    • Total serum bilirubin within normal institutional limits
    • ALT (SGPT) ≤ 2.5× the institutional upper limit of normal OR AST (SGOT) ≤ 2.5× the institutional upper limit of normal
  • Ability to take medication sublingually
  • Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures
  • Accessible for treatment and follow-up
  • Female subjects: Use of two approved forms of contraceptives
  • Male subjects: Use of two approved forms of contraceptives and willing to instruct their partners to use one form of contraceptive as well
  • Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • MGMT promoter methylation status is positive (i.e., promoter is methylated)
  • Prior radiotherapy for GBM within two (2) weeks of entering the study or has not recovered from adverse events due to agents administered more than four (4) weeks earlier
  • Prior chemotherapy, immunotherapy, or radiation therapy for other cancers (except for treatment of limited curable skin cancers)
  • Currently or recently (in the previous six months) part of a clinical trial involving any other investigational agents
  • Hypersensitivity or allergy to any ingredient in the study drug
  • Receiving any medications or substances that are known substantial inhibitors or inducers of CYP3A4
  • Consumption of grapefruit or grapefruit juice three (3) days prior to screening or unwillingness to abstain from consuming grapefruit in any form during the study
  • Uncontrolled intercurrent illness that would limit compliance with study requirements
  • Pregnancy, possible pregnancy, plans for pregnancy, or active lactation or nursing
  • Positive HIV or hepatitis status
  • Unwillingness or inability to take medication sublingually
  • Diagnosis of cancer more than 120 days prior to initial visit
  • History of prior malignancy except curatively treated skin cancers
  • History of prior chemotherapy or radiation for other cancers (except for treatment of limited curable skin cancers) before initial visit
  • Clinically significant unstable medical conditions other than GBM
  • Clinically relevant symptoms or clinically significant illness in the four (4) weeks prior to screening or registration, other than GBM
  • Clinically significant unstable medical conditions, other than GBM, deemed by the investigator to pose an unacceptable risk to the patient
  • History of substance abuse within the last two years
  • Current use of recreational or medicinal cannabis, synthetic cannabinoid-based medications, or alcohol, or planned use while in the study
  • Evidence of any diseases or conditions that may interfere with the study or interpretation of study results
  • Inability or unwillingness to cooperate with the study procedures
  • Known history of severe depression or psychiatric disorders, or active suicidal ideation
  • Subjects with close affiliation with an investigational site
  • Absence of or unwillingness to sign and date the informed consent document
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Philip A Arlen, PhD 4074430656 parlen@leafvertical.com
Contact: William Fisher 407-797-2332 ceo@leafvertical.com
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03687034
Other Study ID Numbers  ICMJE Olympian 2
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Leaf Vertical Inc.
Study Sponsor  ICMJE Leaf Vertical Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Nicholas Avgeropoulos, MD Orlando Health / UF Health Cancer Center
PRS Account Leaf Vertical Inc.
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP